Juno Therapeutics (JUNO) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall St set for steady open as oil jumps ahead of key earnings
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's Russian supply announcements
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- Iren shares jump 5% in premarket trade on report of Anthropic AI cloud deal
Tweet
Share
E-mailGet Alerts JUNO Hot Sheet
Join SI Premium – FREE
Juno Therapeutics (NASDAQ: JUNO) reported Q4 EPS of ($0.53), $0.06 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $4.15 million versus the consensus estimate of $4.79 million.
For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can broadening earnings growth sustain the equity upcycle? JPM weighs in
- Citi maintains buy rating on JD.com with $39 price target
- Elevance (ELV) PT Raised to $460 at Guggenheim
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
